GlassScriptPhysician profile
Kenneth B Camacho
NPI 1750323424
$2,269.73
in general payments reported to CMS, 2019-2025
20 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $28.89 · 2021: $443 · 2022: $474 · 2023: $251 · 2024: $138 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.52 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.58 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Celgene Corporation | $195.71 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $194.96 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $109.05 | 2019 | |
| Mauna Kea Technologies, INC. | $98.90 | 2019 | |
| Boston Scientific Corporation | $77.79 | 2019 | |
| Medtronic USA, INC. | $71.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.84 | 2021 | |
| Allergan, INC. | $49.81 | 2019 | |
| Olympus America INC. | $34.12 | 2024 | Visiglide |
| Janssen Biotech, INC. | $32.61 | 2021-2023 | Simponi Aria, Remicade, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.29 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $20.63 | 2024 | Rebyota |
| Ethicon US, LLC | $18.25 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $15.92 | 2025 | Zenpep |
| Ardelyx, INC. | $15.39 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $12.05 | 2019 | |
| Genzyme Corporation | $11.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,262.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.